Treatment of drug-susceptible and drug-resistant tuberculosis

van der Werf, T. S., Caminero, J. A., Scardigli, A. & Tadolini, M., Dec-2018, Tuberculosis. Migliori, G. B., Bothamley, G., Duarte, R. & Rendon, A. (eds.). European Respiratory Society, Vol. 82. p. 152-178 27 p. (ERS Monograph).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

The treatment of TB, both drug-susceptible and drug-resistant forms, should be based on two principles: 1) the combination of drugs (at least four) to avoid selection pressure resulting in the emergence of DR-TB strains and 2) the need for prolonged treatment in order to sterilise all infectious sites and thus cure the patient and prevent relapses. The selection of drugs should be based on their bactericidal and sterilising properties, their ability to prevent drug resistance and their safety profile. Based on these principles, and on the mode of action of the different drugs, this chapter describes in detail anti-TB treatment, the most appropriate choice of drugs based on in vitro susceptibility testing, starting with
drug-susceptible TB (DS-TB), and a proposal to standardise as much as possible the difficult-to-manage patients with DR-TB. The chapter delineates the recommended treatment for DS-TB, mono- and polyresistant TB, MDR-TB, XDR-TB and forms of TB beyond XDR-TB. Special attention is given to the 2018 WHO guidelines regarding the revised grouping of second-line TB drugs recommended for use in longer MDR-TB regimens, the shorter MDR-TB regimens, the possibility of designing a standardised pre-XDR and XDR-TB regimen adapted to the country, and some relevant management issues.
Original languageEnglish
Title of host publicationTuberculosis
EditorsGiovanni Battista Migliori, Graham Bothamley, Raquel Duarte, Adrian Rendon
PublisherEuropean Respiratory Society
Number of pages27
ISBN (Electronic)978-1-84984-100-9
ISBN (Print)978-1-84984-099-6
Publication statusPublished - Dec-2018

Publication series

NameERS Monograph

View graph of relations

ID: 77164973